GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » EPS (Diluted)

Mosaic ImmunoEngineering (Mosaic ImmunoEngineering) EPS (Diluted) : $-0.13 (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering EPS (Diluted)?

Mosaic ImmunoEngineering's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.04. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.13.

Mosaic ImmunoEngineering's EPS (Basic) for the three months ended in Mar. 2024 was $-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.13.

Mosaic ImmunoEngineering's EPS without NRI for the three months ended in Mar. 2024 was $-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.13.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Mosaic ImmunoEngineering EPS (Diluted) Historical Data

The historical data trend for Mosaic ImmunoEngineering's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering EPS (Diluted) Chart

Mosaic ImmunoEngineering Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.00 -1.33 -0.55 -0.33 -0.14

Mosaic ImmunoEngineering Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 - -0.05 -0.04 -0.04

Competitive Comparison of Mosaic ImmunoEngineering's EPS (Diluted)

For the Biotechnology subindustry, Mosaic ImmunoEngineering's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mosaic ImmunoEngineering's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's PE Ratio distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's PE Ratio falls into.



Mosaic ImmunoEngineering EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Mosaic ImmunoEngineering's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.008-0)/7.236
=-0.14

Mosaic ImmunoEngineering's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.288-0)/7.236
=-0.04

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mosaic ImmunoEngineering  (OTCPK:CPMV) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mosaic ImmunoEngineering EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Mosaic ImmunoEngineering (Mosaic ImmunoEngineering) Business Description

Traded in Other Exchanges
N/A
Address
1537 South Novato Boulevard, Suite 5, Novato, CA, USA, 94947
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. The company has a single operating segment for the purposes of assessing performance and making operating decisions.
Executives
Robert Baffi director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University 10 percent owner 10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King director, officer: President and CEO
Paul J Lytle director, officer: EVP, Chief Financial Officer
Robert L Garnick director C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz director, officer: Chief Scientific Officer 871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry director 315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson director
Donald E Schrock director C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau officer: VP, Business Development MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner officer: Chief Executive Officer MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers officer: Chief Financial Officer C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick director 6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney officer: CFO
Helmut Jr Falk director